| Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine A Sparreboom, J Van Asperen, U Mayer, AH Schinkel, JW Smit, ... Proceedings of the National Academy of Sciences 94 (5), 2031-2035, 1997 | 1119 | 1997 |
| Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan JW Jonker, JW Smit, RF Brinkhuis, M Maliepaard, JH Beijnen, ... Journal of the National Cancer Institute 92 (20), 1651-1656, 2000 | 826 | 2000 |
| Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure JW Smit, MT Huisman, O van Tellingen, HR Wiltshire, AH Schinkel The Journal of clinical investigation 104 (10), 1441-1447, 1999 | 433 | 1999 |
| Phase I dose-escalation study of JNJ-42756493, an oral pan–fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors J Tabernero, R Bahleda, R Dienstmann, JR Infante, A Mita, A Italiano, ... Journal of Clinical Oncology 33 (30), 3401-3408, 2015 | 392 | 2015 |
| Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. U Mayer, E Wagenaar, JH Beijnen, JW Smit, DK Meijer, J van Asperen, ... British journal of pharmacology 119 (5), 1038, 1996 | 370 | 1996 |
| Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin … A Younes, C Thieblemont, F Morschhauser, I Flinn, JW Friedberg, ... The Lancet Oncology 15 (9), 1019-1026, 2014 | 295 | 2014 |
| Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs MT Huisman, JW Smit, KML Crommentuyn, N Zelcer, HR Wiltshire, ... Aids 16 (17), 2295-2301, 2002 | 283 | 2002 |
| Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism AE van Herwaarden, E Wagenaar, CMM van der Kruijssen, ... The Journal of clinical investigation 117 (11), 3583-3592, 2007 | 260 | 2007 |
| P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir MT Huisman, JW Smit, HR Wiltshire, RMW Hoetelmans, JH Beijnen, ... Molecular Pharmacology 59 (4), 806-813, 2001 | 220 | 2001 |
| Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors MT Huisman, JW Smit, AH Schinkel Aids 14 (3), 237-242, 2000 | 211 | 2000 |
| Transport of topoisomerase I inhibitors by the breast cancer resistance protein: potential clinical implications JHM Schellens, M Maliepaard, RJ Scheper, GL Scheffer, JW Jonker, ... Annals of the New York Academy of Sciences 922 (1), 188-194, 2000 | 155 | 2000 |
| Mrp2 is essential for estradiol-17β (β-D-glucuronide)–induced cholestasis in rats L Huang, JW Smit, DK Meijer, M Vore Hepatology 32 (1), 66-72, 2000 | 135 | 2000 |
| Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted JW Smit, AH Schinkel, B Weert, DKF Meijer British journal of pharmacology 124 (2), 416-424, 1998 | 132 | 1998 |
| A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with … B Venugopal, R Baird, RS Kristeleit, R Plummer, R Cowan, A Stewart, ... Clinical Cancer Research 19 (15), 4262-4272, 2013 | 123 | 2013 |
| Contribution of the murine mdr1a P‐glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption JW Smit, AH Schinkel, M Müller, B Weert, DKF Meijer Hepatology 27 (4), 1056-1063, 1998 | 108 | 1998 |
| Effect of CYP 3A perpetrators on ibrutinib exposure in healthy participants J de Jong, D Skee, J Murphy, J Sukbuntherng, P Hellemans, J Smit, ... Pharmacology research & perspectives 3 (4), e00156, 2015 | 103 | 2015 |
| Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency RJ Auchus, EO Buschur, AY Chang, GD Hammer, C Ramm, D Madrigal, ... The Journal of Clinical Endocrinology & Metabolism 99 (8), 2763-2770, 2014 | 87 | 2014 |
| Hepatobiliary elimination of cationic drugs: the role of P-glycoproteins and other ATP-dependent transporters DKF Meijer, JW Smit, M Müller Advanced drug delivery reviews 25 (2-3), 159-200, 1997 | 85 | 1997 |
| Interactions between P‐glycoprotein substrates and other cationic drugs at the hepatic excretory level JW Smit, E Duin, H Steen, R Oosting, J Roggeveld, DKF Meijer British journal of pharmacology 123 (3), 361-370, 1998 | 77 | 1998 |
| The antiperinuclear factor. 1. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. IR Sondag-Tschroots, C Aaij, JW Smit, TE Feltkamp Annals of the Rheumatic Diseases 38 (3), 248-251, 1979 | 69 | 1979 |
